SCHEMBL1003510

SCHEMBL1003510

O=c1cc(OCc2ccc(F)cc2)cc[nH]1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.71
ABL1 P00519 1/20 0.71
PPARG P37231 1/20 0.71
RIN1 Q13671 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
NCOR2 Q9Y618 1/20 0.71
MAOB P27338 14/20 0.52
MAOA P21397 9/20 0.52
ACHE P22303 1/20 0.52
NR4A2 P43354 1/20 0.49
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
PKM P14618 1/20 0.48
CYP2C19 P33261 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14151016 0.84 NSD2 (0.63) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL4243774 0.84 NSD2 (0.54) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL15889565 0.84 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL12949746 0.84 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL1003502 0.84 NSD2 (0.71) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL136664 0.83 NSD2 (1.00) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL3477099 0.83 NSD2 (0.66) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL119148 0.83 NSD2 (0.69) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL15111297 0.82 NSD2 (0.64) NSD2ABL1PPARGRIN1L3MBTL1
SCHEMBL94520 0.80 NSD2 (0.54) NSD2ABL1PPARGRIN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120316200-A1 PYRIDONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-12-13 US claimed
WO-2025094152-A1 18F AND11C RADIOLABELED MCHR1 PET LIGANDS RICHTER GEDEON NYRT. (HU) 2025-05-08 WO disclosed
US-20170204095-A1 (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT 2017-07-20 US disclosed
US-9650378-B2 (1-azinone)-substituted pyridoindoles ALBANY MOLECULAR RESEARCH, INC. (US) 2017-05-16 US disclosed
US-9365540-B2 Benzimidazole derivatives as MCH receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-14 US disclosed
US-20160159798-A1 (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES HARMONY BIOSCIENCES, LLC 2016-06-09 US disclosed
US-9296743-B2 (1-azinone)-substituted pyridoindoles ALBANY MOLECULAR RESEARCH, INC. (US) 2016-03-29 US disclosed
US-9199963-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-01 US disclosed
EP-2802571-A1 BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2014-11-19 EP disclosed
EP-2476680-B1 (1-Azinone)-Substituted Pyridoindoles ALBANY MOLECULAR RES INC (US) 2014-08-27 EP disclosed
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones PFIZER INC 2008-04-10 US disclosed
WO-2008022979-A1 NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 WO disclosed
US-20070208046-A1 Pyridone derivative MSD K.K. (JP) 2007-09-06 US disclosed
EP-1741703-A1 PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208046-A1 Pyridone derivative CHRM1, XDH, MTR NSD2 723/4885ABL1 2427/4885PPARG 2054/4885
US-20120316200-A1 PYRIDONE DERIVATIVES MC1R, MC5R, MCHR1 NSD2 4362/4885ABL1 3252/4885PPARG 194/4885
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 NSD2 4745/4885ABL1 614/4885PPARG 1624/4885
US-20080085884-A1 Melanin Concentrating Hormone Receptor-1 Antagonist Pyridinones MCHR1, MCHR2, MC1R NSD2 3876/4885ABL1 1976/4885PPARG 985/4885
US-20170204095-A1 (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES NR3C2, NR2E3, NR0B1 NSD2 3647/4885ABL1 1074/4885PPARG 172/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 NSD2 4720/4885ABL1 502/4885PPARG 1569/4885
US-20160159798-A1 (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES NR3C2, NR2E3, NR0B1 NSD2 3647/4885ABL1 1074/4885PPARG 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.